XOLREMDI MOA Animation 

X4 Pharmaceuticals needed a 3D medical animation for the launch of their new therapeutic, XOLREMDITM, to help treat WHIM syndrome.

One of the main goals was to communicate to healthcare professionals that WHIM syndrome is complex, and XOLREMDI cuts through this complexity, by targeting the underlying cause of the disease.

Therefore, in the script, we first detailed the many manifestations amongst patients with WHIM syndrome and showed how myelokathexis (the failure of neutrophils to leave the bone marrow) is present in nearly 100% of patients. Then we introduce how variants of a protein called CXCR4 lead to retention of white blood cells in the bone marrow and reduction of white blood cells circulating in the blood. By targeting this one receptor, white blood cells could migrate to the periphery to perform their functions.

It was important to link the molecular variant to the cellular effect, therefore we chose to render a yellow glowing tail of the protein (the location of the main difference in the CXCR4 variant), and have corresponding yellow glows within the overmature neutrophil with its dark, multi-lobed nucleus.

Creatively, for the cellular story we chose to have the camera itself behave like a cell. When we describe migration into the circulation, the camera follows, and when we discuss retention in the bone marrow, the camera gets trapped as well.

Visual assets from the animation were also included in other materials, including a detail aid for healthcare professionals.

Through meticulous planning and execution, we successfully created visuals that effectively communicate WHIM syndrome and XOLREMDI, aiding in healthcare professional understanding.